webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

MC-PEG2-NH2

  CAS No.: 640267-62-5   Cat No.: BADC-01720 4.5  

MC-PEG2-NH2 is a maleimide-PEG2 amine ADC linker intermediate designed for thiol-specific conjugation and improved payload stability in antibody-drug conjugates. Keywords: ADC linker, maleimide linker, PEG spacer, thiol conjugation, payload delivery.

MC-PEG2-NH2

Structure of 640267-62-5

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C16H27N3O5
Molecular Weight
341.40

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
IUPAC Name
N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-6-(2,5-dioxopyrrol-1-yl)hexanamide
Canonical SMILES
C1=CC(=O)N(C1=O)CCCCCC(=O)NCCOCCOCCN
InChI
InChI=1S/C16H27N3O5/c17-7-10-23-12-13-24-11-8-18-14(20)4-2-1-3-9-19-15(21)5-6-16(19)22/h5-6H,1-4,7-13,17H2,(H,18,20)
InChIKey
BRPNMDKROWMZAK-UHFFFAOYSA-N

In the realm of drug delivery, MC-PEG2-NH2 (methoxy-capped polyethylene glycol amine) plays a pivotal role due to its unique properties. This bifunctional polyethylene glycol derivative acts as a versatile linker, enabling the conjugation of therapeutic agents, which can significantly enhance their solubility, stability, and bioavailability. These enhancements are crucial for optimizing drug performance, particularly for pharmaceuticals that are poorly soluble or unstable in biological environments. Furthermore, MC-PEG2-NH2 facilitates the creation of long-circulating drug carriers by preventing rapid renal clearance and reducing immunogenicity. This ability to modify pharmacokinetics extends the therapeutic window and effectiveness of various treatments, making it an invaluable tool in the development of new drug delivery systems.

In the field of protein and peptide modification, MC-PEG2-NH2 serves as an essential reagent for enhancing protein stability and solubility. By providing a flexible and hydrophilic spacer, it helps in reducing protein aggregation, which is a common issue leading to loss of biological activity and stability. Moreover, PEGylation, using MC-PEG2-NH2, can improve the half-life of proteins and peptides in the bloodstream, thus increasing their therapeutic efficacy. This modification also mitigates immunogenicity and antigenicity, allowing therapeutic proteins and peptides to maintain their function longer in the body and enabling their use in a wider range of therapeutic applications.

In the context of nanoparticle technology, MC-PEG2-NH2 is instrumental in improving the biocompatibility and functionality of nanoparticles used in various applications. It acts as a surface modifier, ensuring that nanoparticles exhibit reduced opsonization and enhanced circulation time in the body. The polyethylene glycol moiety provides a "stealth" characteristic, helping nanoparticles evade the immune system and accumulate preferentially in target tissues. This property is particularly advantageous in cancer therapy, where targeted delivery of nanoparticles can increase drug concentration at the tumor site while minimizing systemic side effects. MC-PEG2-NH2 thus supports the design of next-generation nanoparticle-based therapeutic and diagnostic agents.

In diagnostic and imaging applications, MC-PEG2-NH2 is utilized to enhance the performance of imaging agents and biosensors. By modifying imaging probes and sensors, it helps in reducing nonspecific interactions with biological matrices, leading to sharper signals and increased specificity. This improvement is vital for accurate diagnostics, allowing for the detection of biomarkers at lower concentrations and facilitating early disease detection. Additionally, the application of MC-PEG2-NH2 in imaging agents improves their pharmacokinetic profiles, resulting in better tissue penetration and retention, thus providing more detailed and informative imaging results. Overall, the use of MC-PEG2-NH2 in these areas contributes to the advancement of various diagnostic and imaging modalities, expanding their clinical and research applications.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Maleimide-PEG2-hydrazide TFA
Send Inquiry
Verification code
Inquiry Basket